echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Run new biological class 1 innovative drug completed the first clinical treatment of glioma phase 2 clinical treatment.

    Run new biological class 1 innovative drug completed the first clinical treatment of glioma phase 2 clinical treatment.

    • Last Update: 2020-08-17
    • Source: Internet
    • Author: User
    Tags

    multi

    bio 4

    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Today, Suzhou Runxin Biotech Co., Ltd. (hereinafter known as Runxin Bio) announced that the company in the new drug RX108 treatment of relapsed glioblastoma phase 2 clinical study recently completed the first patient administration at Fudan University affiliated Huashan Hospital.
    RX108 is a type of innovative drug with global intellectual property rights developed by Runxin Bio, is a novel Na-K-ATP enzyme inhibitor, with a "one-goal multi-point" mechanism, can play an anti-tumor role through a variety of ways.
    currently, the drug is conducting a number of clinical studies on different solid tumors in China and the United States.
    is known that this completed clinical study of the first patient administration is a single-arm, open, multi-center Phase 2 clinical trial designed to evaluate the effectiveness and safety of patients with glioblastoma who have progressed or relapsed in RX108 after standard treatment.
    public data show that brain tumors account for 1.4% of all tumors, about 300,000 new people are added globally each year, and about 100,000 new in China each year.
    glioblastoma (GBM) is the most aggressive type of brain tumor.
    Note: The original text has a limitation.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.